Back to top

The Zacks Analyst Blog Highlights: Amazon, Verizon, AbbVie, Lowe???s and Chubb

Read MoreHide Full Article

For Immediate Release

Chicago, IL – January 24, 2019 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Amazon (AMZN - Free Report) , Verizon (VZ - Free Report) , AbbVie (ABBV - Free Report) , Lowe’s (LOW - Free Report) and Chubb (CB - Free Report) .

Here are highlights from Wednesday’s Analyst Blog:

Top Research Reports for Amazon, Verizon and AbbVie

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Amazon, Verizon and AbbVie. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today’s research reports here >>>

Buy-rankedAmazon’s shares have outperformed the broader market in the past year by a wide margin (the stock is up +20.3% vs. the -7.1% decline for the S&P 500 as a whole). The Zacks analyst thinks Amazon’s strengthening retail position, riding on its growing global footprint and distribution strength remains its key growth driver.

Moreover, robust Prime and its benefits are aiding its retail business. Also, rapid expansion of Prime enabled grocery services and growing physical presence are tailwinds. Further, increasing AWS regions and its growing adoption will continue to aid Amazon’s cloud momentum. Also, rising number of Alexa compatible devices are a major positive. Amazon's strong holiday initiatives have boosted its holiday performance.

Estimates have been going up ahead of the company’s Q4 earnings release. The company has positive record of earnings surprises in recent quarters. However, its sales outlook for holiday season is weak due to changes in Indian holiday timing. Also, rising cloud battle and heavy investment in fulfillment centers are headwinds.

Shares of Buy-ranked Verizon have gained +5.1% in the past year, outperforming the Zacks Wireless National industry’s decline of -4.4% during the same period. The Zacks analyst thinks Verizon remains poised to benefit from the upcoming 5G boom, driven by healthy traction in the wireless business.

The company is further seeking a first mover advantage in the 5G race as it plans to launch commercial 5G smartphones in the market in the first half of 2019 in collaboration with Samsung. Focus on online content delivery, mobile video and online advertising should also drive future growth.

In the enterprise and the wholesale business, Verizon is changing its revenue mix toward newer growth services like cloud, security and professional services. Management is bullish on the industry's ability to grow revenues from smartphones, tablets and cloud computing and has reiterated its earlier guidance. However, Verizon continues to struggle in a competitive and saturated U.S. wireless market, where spectrum crunch has become a major issue, hurting its profitability.

AbbVie’s shares have gained +11.6% in the past three months, outperforming the Zacks Large-Cap Pharmaceuticals industry's increase of +2%. The Zacks analyst thinks AbbVie’s key drug, Humira has been performing well based on strong demand trends despite new competition. Moreover, Imbruvica has multibillion dollar potential. Mavyret’s launch has also been stronger than expected. AbbVie has also been successful in expanding approvals for its cancer drugs, Imbruvica and Venclexta.

AbbVie has a strong late-stage pipeline comprising several products with multibillion-dollar potential expected to be launched in the near term. AbbVie expects to launch more than 20 new products or line extensions of marketed drugs before Humira biosimilar competition begins in the United States in 2023. However, direct biosimilar competition to Humira in Europe from October can erode revenues in 2019. Nonetheless, estimates have gone up ahead of Q4 earnings. AbbVie has a positive record of earnings surprises in the recent quarters.

Other noteworthy reports we are featuring today include Lowe’s and Chubb.

Zacks' Top 10 Stocks for 2019

In addition to the stocks discussed above, wouldn't you like to know about our 10 finest buy-and-holds for the year?

From more than 4,000 companies covered by the Zacks Rank, these 10 were picked by a process that consistently beats the market. Even during 2018 while the market dropped -5.2%, our Top 10s were up well into double-digits. And during bullish 2012 – 2017, they soared far above the market's +126.3%, reaching +181.9%.

This year, the portfolio features a player that thrives on volatility, an AI comer, and a dynamic tech company that helps doctors deliver better patient outcomes at lower costs.

See Stocks Today >>

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com                                   

http://www.zacks.com                                                 

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.



More from Zacks Press Releases

You May Like